About
Who we are
Axbio Biotechnology
As a global leader in integrated circuit biotechnology, AXBIO is committed to developing a next-generation electrochemical detection platform to transform the life sciences tools and diagnostics industry. At the intersection of IC(integrated circuits), BT(biotechnology), and AI(artificial intelligence), we are committed to creating advanced foundational platforms for life science research and clinical applications.
-
12 inchesNanopore sequencing wafer in mass-production
-
50+Global Patent Authorization/ Global patents granted
-
~ 60%Percentage of R&D staff/ Proportion of R&D personnel
-
~4100㎡GMP Production Center
-
MissionDiscover the source code of life, safeguard the well-being of all -
VisionTo be a pioneer in building the foundational platforms of life sciences -
ValuesHonesty and Integrity, Result Oriented, Continuous Innovation, Resilient accountability, Teamwork
CORE TEAM
Core Team
TIAN HUI/CEO
- PhD & MS, Stanford University; MS & BS, Tsinghua University, China
- VP at InVisage, and Design Director at Pixim
- Over 100 granted patents globally
- Responsible for InVisage's quantum-dot image sensor chip (acquired by Apple) and Pixim's various image sensor products (acquired by Sony)
Igor Ivanov/COO
- PhD & MS, Saint Petersburg State University, Russia
- Former VP of InVisage and Intermolecular
- Founder, CEO and CTO of Blue29
- Served in CuTek、Mattson、AMD
- Over 100 granted patents globally
- Responsible for Invisage's quantum-dot process development and production, Blue29's superalloy nanomaterials and processes (acquired by KLA Tencor), CuTek's electroplating equipment (acquired by Mattson), and Intermolecular’s material development (listed on NASDAQ)
development history
Our History
development history
Our History
3350 Scott Blvd # B-9, Santa Clara, CA 95054, U.S.A.
info@axbio.co
+1-408-642-1287
Copyright ©Axbio Inc. All rights reserved.